[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene, page-39

DJ fair enough you don't rate the interview. I agree it's unlikely to drive any impact on the share price.

However it's more likely to enhance new investor awareness, potential buying and potentially resultant share price appreciation - than not doing an interview.

I'd also argue it doesn't consume much of Dr Tillet's time. The spiel he knows back to front now and it was 4 minutes in duration. Assuming they also have direct cost... I can't imagine it's endangering the trials budgets.

Fine if you're just venting steam, I get tired of the mind numbing, eye watering carry on about selling investment properties etc sometimes, but is there something you consider to be a more constructive use of, that, lets say, hour of management team time?